OncoBeta GmbH, a medical device company specializing in innovative epidermal radioisotope therapies, has confirmed the completion of recruitment for its phase IV international multi-centre study. The study, called EPIC-Skin, aims to evaluate the efficacy of Rhenium-SCT® in treating non-melanoma skin cancer (NMSC) and assess important patient reported outcome measures such as quality of life and cosmetic outcomes. The treatment involves a non-invasive application of a paste containing ß-emitting particles directly to the lesion, eliminating cancer cells without surgery. The study is being conducted across five countries and seven major cities with over 180 patients participating. An interim analysis is expected to be published in mid-2023. NMSC is the most common form of cancer in humans, and traditional treatments involve surgery, which can result in scarring or loss of function.
Tue, 11 Jul 2023 09:05:00 GMT | PR Newswire